

1st July 2025

Press Release

Notification of entering a fundamental agreement of business alliance with artience Co., Ltd.

Please to announced that we, Immuno-Biological Laboratories, Co., Ltd. (“**IBL**”) and artience Co., Ltd. (Chuo-ku, Tokyo, CEO: Satoru Takashima, “**artience**”) signed a fundamental agreement of business alliance in life science related business such as reagents and materials used in research and in-vitro diagnostic field.

【Aim of the business alliance】

The life sciences market has been continuously and globally growing due to increasing importance of in-vitro diagnostic products triggered by increasing demand of biopharmaceuticals products and pandemics. In line with this situation, research reagents for using drug screening, genetic and antibody testing, etc., are more sophisticated, on the other hand there are outstanding issues in improving accuracy of antigen-antibody reactions used for these purposes, as well as in the quality variability and procurement stability of raw materials of biological origin. It has been attracting attention for the application of chemically synthesized materials in recent years as an improving or alternative options on these matters.

We are operating businesses of research reagent and in vitro diagnostic products as one of the leading antibody manufacturers more than 40 years since establish the company in Japan. We have a high technical competence for antibody development and have been also accelerating development of the overseas market where there is high demand at the result our overseas sale ratio has reached 40% in recent years.

artience has indicated biotechnology field as one of their next-generation businesses in their medium-term management plan, and they are working on creating new businesses in this field of developing near-infrared fluorescent probes for high-sensitivity imaging and functional polymers for in-vitro diagnostic use, based on their core materials, which is color materials and polymers. In particular, they have been accumulating their actual results and effectiveness of their synthetic polymers for use in in-vitro diagnostics and research reagents such as its effectiveness for significantly suppress of quality variability which is uniquely identified outstanding issue of biologically derived raw materials and improving sensitivity of antigen-antibody reactions have been recognized in the market.

In this business alliance, our technologies with regard to antibodies, reagent kits, and in-vitro diagnostic products are combined with polymer materials and chemical synthesis technologies held by artience to improve quality and stability of antibodies. We are aiming to provide original high-quality

products worldwide through developing more accurate and stable in vitro diagnostic products and test reagents without using any biologically derived protein.

【Future prospects】

The impact of this business alliance on our performance will be minor, however, in that case it becomes clear that there will be any impact on our financial results in the future through any specific product development progress, it will be announced as soon as possible. In addition, we believe that the commitment of this business alliance will contribute to enhancing our corporate value in the mid-long term.

About Immuno-Biological Laboratories Co., Ltd. (IBL)

IBL has been researching “antibody” which is an essential immune mechanism for maintaining biologically living and pursuing development of antibodies against proteins involved in brain and nerve diseases, cancer, autoimmune diseases and other diseases through its unique antibody development technologies since IBL was established in 1982. IBL has more than 1,000 antibodies which are related to our main focused fields Alzheimer's disease, lifestyle-related diseases and cancers etc. We supply diagnostic products, diagnostic raw materials and research reagents to universities, pharmaceutical companies and other research institutions etc. in both global and domestic market.

For more information, please visit our website: (<https://www.ibl-japan.co.jp/en/>)

About artience Co., Ltd. (artience)

artience is a chemical company established in 1896 that develops and proposes fine chemical materials (Company name at the time of incorporation: Toyo Ink Mfg. Co., Ltd.). It operates in four segments: color and functional materials, polymers and coating, packaging, printing and information. artience also expands their business in various fields such as energy, electronics and bio-healthcare. artience group is a company who delivers pioneering values to people around the world using cutting-edge technology and working on realization of a prosperous future by creating values witch touch your heart. For more information, please visit their website: (<https://www.artiencegroup.com>).

END